Clinical Trials

By Marta Catalfamo

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas – INSTAL-101

Principal Investigators: Beth Israel Deaconess Medical Center. Boston, Massachusetts, United States, 02215

Contact: Eisai Medical Information, Phone: 1-888-274-2378 Identifier: NCT04144140

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Principal Investigators: Humphrey Gardner, Chief Medical Officer, MD, FCAP. Silicon Therapeutics. Boston, MA. United States, 02210

Contact: Salah Nabhan, MS   Phone: 479)530-3530 Identifier: NCT04609579

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Principal Investigators: Sunyoung Lee, MD. M.D. Anderson Cancer Center. Houston, Texas, United States, 77030

Contact:  Sunyoung Lee,  Phone: 713-792-2828 Identifier: NCT04380545

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Mel66)

Principal Investigators: Craig L Slingluff, Jr, Professor of Surgery; Director, Human Immune Therapy Center, University of Virginia. Charlottesville, Virginia, United States, 22908.

Contact:  Adela Mahmutovic, BS  Phone: 14349826714 Identifier: NCT04364230

Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients (INTERCOP)

Principal Investigators: Emanuele Bosi, Professor. IRCCS Ospedale San Raffaele. Milano, Italy, 20132

Contact:  Patrizia Rovere Querini, Professor  Phone: 00390226426768 Identifier: NCT04449380

Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients

Principal Investigators: Brahm H. Segal, MD. Roswell Park Cancer Institute. Buffalo, New York, United States, 14263  

Contact:  Pawel Kalinski, MD, Phone: 716-845-5721 Identifier: NCT04379518

Study of SRF388 in Patients With Advanced Solid Tumors

Principal Investigators: Daniel Morgensztern, MD, Washington University School of Medicine – St. Louis. Saint Louis, Missouri, United States, 63110

Contact:  Jessica Archambault,  Phone: 314-362-8246 Identifier: NCT04374877

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) (BEAT-2)

Principal Investigators: Luis J Montaner, DVM, DPhil. The Wistar Institute. University of Pennsylvania. Philadelphia, Pennsylvania, United States, 19104

Contact:   Pablo Tebas, M.D, Phone: 215-662-8217 Identifier: NCT03588715

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Principal Investigators: Milos Miljkovic, M.D. National Cancer Institute. National Institutes of Health Clinical Center. Bethesda, Maryland, United States, 20892

Contact:   NCI Medical Oncology Referral Office, Phone: (240) 760-6050 Identifier: NCT03759184

Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Principal Investigators: Nada Alachkar, MD. Johns Hopkins Hospital. Baltimore, Maryland, United States, 21287

Contact:  Study Manager Phone: 4105508858 Identifier: NCT04363502

Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients’

Principal Investigators: Brahm H Segal, MD. Roswell Park Cancer Institute. Buffalo, New York, United States, 14263

Contact:  Pawel Kalinski , MD Phone: 716-845-5721 Identifier: NCT04379518

Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 (ILIAD)

Principal Investigators: Jordan Feld, MD. Toronto General Hospital. Toronto, Ontario, Canada, M5G 2C4

Contact:  Seham Noureldin, PhD, Phone: 416-340-4800 ext 8681 Identifier: NCT04354259

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)

Principal Investigators: Andrej SPEC, MD. Washington University. Saint Louis, Missouri, United States, 63110

Contact:  Andrej SPEC, MD, Phone: 314-747-1725 Identifier: NCT04154826